The Priority Review

Tag

Rheumatoid Arthrits

1 story

Stories

  1. Clinical trials

    Jiankuan registers Phase 3 trial of proximod in rheumatoid arthritis

    The study, led by Jiankuan (Suzhou) Biotechnology Company Limited, plans to enroll 590 participants and begin on October 15, 2026. It is to evaluate different doses of proximod in moderate-to-severe active rheumatoid arthritis subjects with inadequate response or intolerance to bDMARDs and/or tsDMARDs.